Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
Weight Watchers Med+ Establishes Access to GLP-1s Through Medicare GLP-1 Bridge Program
08:00am, Tuesday, 30'th Jun 2026
Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program. Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medi
Eli Lilly Is Dominating the GLP-1 Market: Here's What a $5,000 Investment Could Look Like in 5 Years
03:00am, Tuesday, 30'th Jun 2026
Eli Lilly could capitalize on the growing GLP-1 market and deliver strong returns through 2031. However, investors need to keep several risks in mind.
Global Partners LP Announces Full Redemption of Series B Fixed Rate Cumulative Redeemable Perpetual Preferred Units
04:05pm, Monday, 29'th Jun 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global”) today announced that it intends to redeem all $75,000,000 of its 3,000,000 issued and outstanding Series B Fixed Rate Cum
Citi says Wegovy pill outpacing rivals as oral GLP-1 race heats up
04:58am, Monday, 29'th Jun 2026
Citi has said Novo Nordisk's (NYSE:NVO) Wegovy pill is outpacing its rivals in the United States, even as competition in the oral weight-loss market intensifies. The broker's prescription tracker show
CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock
12:30am, Saturday, 27'th Jun 2026
CVS Health announced a program to help patients get easier access to GLP-1 medicines. This initiative could lead to stronger revenue for the company.
GLP-1s linked to smell and taste impairment in diabetes patients
10:45am, Friday, 26'th Jun 2026
We also report on a potentially simple solution to nausea experienced by cancer patients receiving morphine for pain.
Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule
09:10am, Thursday, 25'th Jun 2026
Kelowna, British Columbia – June 25, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces
Walgreens Pharmacists Help Medicare Patients Navigate New Access to GLP‑1 Medications
08:00am, Thursday, 25'th Jun 2026
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is supporting the more than 56 million patients in the Medicare network that may be eligible for GLP-1 medications through the Medicare GLP-1 Bridge program
Bank sees structural strength in GLP-1 market as obesity drives demand
09:08am, Wednesday, 24'th Jun 2026
UBS says the market for GLP-1 obesity and diabetes drugs remains structurally strong, with obesity the key driver of growth, in a note backing its positive stance on the sector's key suppliers. The ba
Global Partners (GLP) Surges 6.9%: Is This an Indication of Further Gains?
04:01am, Wednesday, 24'th Jun 2026
Global Partners (GLP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near te
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
02:36am, Wednesday, 24'th Jun 2026
Eli Lilly's orforglipron type-2 diabetes and obesity pill could launch in China as soon as later this year, an executive at the U.S. drugmaker told Reuters, as rival Novo Nordisk seeks to catch
Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?
10:14am, Tuesday, 23'rd Jun 2026
Eli Lilly is already a market leader in the GLP-1 market, but its high valuation could limit future gains. Viking Therapeutics doesn't have an approved product just yet, but VK2735 has shown a lot of
Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule
09:25am, Tuesday, 23'rd Jun 2026
Potentially valuable novel compositions being investigated Lexaria also receives additional new granted patent
Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple asce
CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
08:00am, Monday, 22'nd Jun 2026
New $50 monthly copay for eligible Medicare patients, one-on-one pharmacist guidance, and over-the-counter products to help manage common side effects available to support patients MinuteClinic® ex
